147 related articles for article (PubMed ID: 11772005)
1. Structural mechanism for heparin-binding of the third Kunitz domain of human tissue factor pathway inhibitor.
Mine S; Yamazaki T; Miyata T; Hara S; Kato H
Biochemistry; 2002 Jan; 41(1):78-85. PubMed ID: 11772005
[TBL] [Abstract][Full Text] [Related]
2. Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site.
Enjyoji K; Miyata T; Kamikubo Y; Kato H
Biochemistry; 1995 May; 34(17):5725-35. PubMed ID: 7727433
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor.
Petersen LC; Bjørn SE; Olsen OH; Nordfang O; Norris F; Norris K
Eur J Biochem; 1996 Jan; 235(1-2):310-6. PubMed ID: 8631347
[TBL] [Abstract][Full Text] [Related]
4. Tissue factor pathway inhibitor; its structure, function and clinical significance.
Kato H
Pol J Pharmacol; 1996; 48(1):67-72. PubMed ID: 9112630
[TBL] [Abstract][Full Text] [Related]
5. The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa.
Burgering MJ; Orbons LP; van der Doelen A; Mulders J; Theunissen HJ; Grootenhuis PD; Bode W; Huber R; Stubbs MT
J Mol Biol; 1997 Jun; 269(3):395-407. PubMed ID: 9199408
[TBL] [Abstract][Full Text] [Related]
6. Contribution of regions distal to glycine-160 to the anticoagulant activity of tissue factor pathway inhibitor.
Lockett JM; Mast AE
Biochemistry; 2002 Apr; 41(15):4989-97. PubMed ID: 11939795
[TBL] [Abstract][Full Text] [Related]
7. Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding.
Piro O; Broze GJ
Circulation; 2004 Dec; 110(23):3567-72. PubMed ID: 15557366
[TBL] [Abstract][Full Text] [Related]
8. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin.
Wesselschmidt R; Likert K; Huang Z; MacPhail L; Broze GJ
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):661-9. PubMed ID: 8292716
[TBL] [Abstract][Full Text] [Related]
9. Tissue factor pathway inhibitor binds to platelet thrombospondin-1.
Mast AE; Stadanlick JE; Lockett JM; Dietzen DJ; Hasty KA; Hall CL
J Biol Chem; 2000 Oct; 275(41):31715-21. PubMed ID: 10922378
[TBL] [Abstract][Full Text] [Related]
10. Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant.
Zhang E; St Charles R; Tulinsky A
J Mol Biol; 1999 Feb; 285(5):2089-104. PubMed ID: 9925787
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces.
Hamamoto T; Yamamoto M; Nordfang O; Petersen JG; Foster DC; Kisiel W
J Biol Chem; 1993 Apr; 268(12):8704-10. PubMed ID: 8473315
[TBL] [Abstract][Full Text] [Related]
12. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8.
Cunningham AC; Hasty KA; Enghild JJ; Mast AE
Biochem J; 2002 Oct; 367(Pt 2):451-8. PubMed ID: 12117418
[TBL] [Abstract][Full Text] [Related]
13. The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa.
Peraramelli S; Suylen DP; Rosing J; Hackeng TM
Thromb Haemost; 2012 Aug; 108(2):266-76. PubMed ID: 22627666
[TBL] [Abstract][Full Text] [Related]
14. Activity of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor.
Johnson K; Zaror I; Bauer D; Choi Y; Creasey A; Innis M
Thromb Haemost; 1998 Oct; 80(4):585-7. PubMed ID: 9798974
[TBL] [Abstract][Full Text] [Related]
15. The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor.
Hamamoto T; Kisiel W
Blood Coagul Fibrinolysis; 1996 Jun; 7(4):470-6. PubMed ID: 8840000
[TBL] [Abstract][Full Text] [Related]
16. Structure and biology of tissue factor pathway inhibitor.
Bajaj MS; Birktoft JJ; Steer SA; Bajaj SP
Thromb Haemost; 2001 Oct; 86(4):959-72. PubMed ID: 11686353
[TBL] [Abstract][Full Text] [Related]
17. Effect of heparin chain length on the interaction with tissue factor pathway inhibitor (TFPI).
Xu X; Takano R; Nagai Y; Yanagida T; Kamei K; Kato H; Kamikubo Y; Nakahara Y; Kumeda K; Hara S
Int J Biol Macromol; 2002 Jun; 30(3-4):151-60. PubMed ID: 12063117
[TBL] [Abstract][Full Text] [Related]
18. The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo.
Warshawsky I; Bu G; Mast A; Saffitz JE; Broze GJ; Schwartz AL
J Clin Invest; 1995 Apr; 95(4):1773-81. PubMed ID: 7706485
[TBL] [Abstract][Full Text] [Related]
19. Structural requirements of human tissue factor pathway inhibitor (TFPI) and heparin for TFPI-heparin interaction.
Ye Z; Takano R; Hayashi K; Ta TV; Kato H; Kamikubo Y; Nakahara Y; Kumeda K; Hara S
Thromb Res; 1998 Mar; 89(6):263-70. PubMed ID: 9669748
[TBL] [Abstract][Full Text] [Related]
20. Bacterial expression, purification, and partial characterization of amino acids 94-155 of human tissue factor pathway inhibitor (TFPI) as an inhibitor of blood coagulation factor Xa.
Day KC; Welsch DJ
Thromb Res; 1992 Dec; 68(4-5):369-81. PubMed ID: 1290165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
